Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 19, 2014

Primary Completion Date

December 17, 2014

Study Completion Date

February 9, 2016

Conditions
Advanced Solid TumorsLymphoma
Interventions
DRUG

IXAZOMIB

"Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity."

Trial Locations (1)

Unknown

Cleveland

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT01953783 - Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB | Biotech Hunter | Biotech Hunter